Deutsche Bank’s Benitec Biopharma BNTC Stock Holding History

Deutsche Bank’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$214K	Buy	20,102 +7,795	+63%	+$90.3K	﹤0.01%	2976
2025 Q4	$166K	Sell	12,307 -4,438	-27%	-$61.4K	﹤0.01%	3104
2025 Q3	$235K	Buy	16,745 +5,792	+53%	+$73.9K	﹤0.01%	2978
2025 Q2	$128K	Buy	+10,953	New	+$153K	﹤0.01%	3165
2020 Q2	–	Sell	-3	Closed	–	–	4262
2020 Q1	$0	Sell	3 -11	-79%	-$1.29K	﹤0.01%	4364
2019 Q4	$1K	Buy	+14	New	+$2.11K	﹤0.01%	4899
2017 Q3	–	Sell	-4	Closed	-$1K	–	4876
2017 Q2	$1K	Buy	+4	New	+$2.53K	﹤0.01%	4853

Other funds holding BNTC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Deutsche Bank's BNTC Position: Q1 2026 in Review

Deutsche Bank increased its Benitec Biopharma (BNTC) stake by 63% in Q1 2026, buying an estimated $90.3K and bringing the position to 20,102 shares worth $214K. The position accounts for ﹤0.01% of the portfolio, ranked #2976.

Deutsche Bank first reported a position in BNTC in Q2 2017 and has held it in 7 quarters since. The position peaked at $235K in Q3 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

Deutsche Bank held 20,102 shares of Benitec Biopharma worth $214K as of Q1 2026.
Deutsche Bank bought 7,795 Benitec Biopharma shares in Q1 2026, an estimated $90.3K.
Benitec Biopharma made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #2976 holding.
Deutsche Bank first reported a position in Benitec Biopharma in Q2 2017 and has held it in 7 quarters since.
Deutsche Bank's Benitec Biopharma position peaked at $235K in Q3 2025.
88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.